Buy Now
Cell Expansion Market Size, Share, Growth & Industry Analysis, By Product (Consumables, Instruments), By Cell (Human, Animal, Microbial, Others), By Application (Biopharmaceuticals, Tissue Culture & Engineering, Gene Therapy, Drug Screening & Development, Others), By End Use Industry, and Regional Analysis, 2024-2031
Pages: 210 | Base Year: 2023 | Release: May 2025 | Author: Versha V.
The market focuses on the large-scale production of cells for use in research, clinical, and commercial applications. It supports advancements in regenerative medicine, cancer therapy, and stem cell research.
This market includes a range of products such as instruments, media, reagents, and cell culture systems. The report highlights key market drivers, major trends, regulatory frameworks, and the competitive landscape shaping the market.
The global cell expansion market size was valued at USD 16.78 billion in 2023 and is projected to grow from USD 19.02 billion in 2024 to USD 47.50 billion by 2031, exhibiting a CAGR of 13.97% during the forecast period. The rise in chronic and infectious diseases is significantly driving the market.
The global prevalence of conditions like cancer, diabetes, and autoimmune disorders continues to increase, boosting the demand for advanced therapeutic solutions, including cell-based treatments. Additionally, the ongoing need for vaccines and biologics to combat infectious diseases is fueling the demand for cell expansion technologies.
Major companies operating in the cell expansion industry are Thermo Fisher Scientific Inc, DH Life Sciences LLC, Merck KGaA, Sartorius AG, Corning Incorporated, Lonza, BD, Eppendorf SE, FUJIFILM Europe GmbH, Terumo BCT, Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc, PromoCell, and HiMedia Laboratories.
The expansion of manufacturing capacity to meet rising demand for advanced cell therapies is significantly driving the market by enabling faster global distribution. Advanced treatments are becoming more widely available with increased production capabilities, which, in turn, accelerates their adoption across different regions. The market is further fueled by the ability to rapidly introduce new products into emerging markets.
Market Driver
Technological Advancements in Cell Expansion Systems
Technological advancements in cell expansion systems are driving the market. Modern platforms now feature real-time monitoring of cell health and metabolic activity, enabling precise adjustment of culture conditions to optimize growth. Advanced systems are minimizing contamination risks and reducing manual intervention.
These advancements are improving the consistency, efficiency, and reproducibility of cell expansion processes, supporting the growing demand for high-quality cells used in cell and gene therapies, personalized medicine, and clinical manufacturing.
Market Challenge
Complexity in Scaling Up Production
Scaling up cell expansion processes while ensuring that cells retain their functionality and quality is a significant technical challenge. Maintaining uniformity and consistency becomes difficult as production volumes increase, particularly when moving from laboratory-scale to commercial-scale operations.
The risk of losing cell viability or functionality during the expansion process also grows, which can lead to costly delays and compromised product quality.
Companies are investing in more sophisticated bioreactor systems that can maintain optimal growth conditions over larger batches, improving reproducibility and consistency. The development of closed-system bioreactors is helping ensure aseptic conditions and reducing the risk of contamination.
Additionally, companies are leveraging Artificial Intelligence (AI) and Machine Learning (ML), to optimize growth parameters and predict outcomes, thereby enhancing control during the scaling process.
Market Trend
Shift Toward Automated and Closed-system Expansion
The cell expansion market is shifting toward the use of automated and closed-system technologies to enhance process efficiency, safety, and scalability. Traditional open and manual cell culture methods are prone to contamination, human error, and batch variability.
In contrast, automated closed systems such as single-use bioreactors and integrated cell processing platforms are minimizing these risks while ensuring consistent product quality.
Moreover, automation reduces labor intensity and supports GMP compliance, making it ideal for clinical and commercial manufacturing. Such innovations are becoming essential for achieving cost-effective and scalable cell expansion as the demand for cell therapies grows.
Segmentation |
Details |
By Product |
Consumables (Reagents, Media, SERA, Vessels), Instruments (Automated Cell Expansion Systems, Cell Counters, Centrifuges, Bioreactors, Others) |
By Cell |
Human, Animal, Microbial, Others, |
By Application |
Biopharmaceuticals, Tissue Culture & Engineering, Gene Therapy, Drug Screening & Development, Stem Cell Research, Others |
By End Use Industry |
Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Hospitals, Others |
By Region |
North America: U.S., Canada, Mexico |
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
South America: Brazil, Argentina, Rest of South America |
Market Segmentation:
Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
North America accounted for 35.95% share of the cell expansion market in 2023, with a valuation of USD 6.03 billion. This market dominance is driven by significant investments in large-scale manufacturing and R&D infrastructure. The region is registering the establishment of multiple advanced facilities dedicated to producing innovative therapies, including cell and gene therapies.
A strong push toward domestic end-to-end production is improving supply chain resilience and ensuring faster delivery of critical treatments. Additionally, the presence of research hubs in innovation-driven areas is accelerating technological advancements.
The cell expansion industry in Asia Pacific is set to grow at a robust CAGR of 14.81% over the forecast period. This growth is fueled by rapid advancements in regenerative medicine and strong collaborations in biotechnological innovation.
The region benefits from increasing investments in R&D, as demonstrated by the development of advanced technologies like real-time monitoring systems and stable cell product manufacturing. Local firms are also focused on commercializing next-generation cell expansion systems, enhancing both quality and process optimization. These efforts are supported by a skilled workforce and expanding healthcare infrastructure.
Market participants in the cell expansion market are focusing on strategic acquisitions and market expansions. They are enhancing their T cell expansion and manufacturing capabilities by acquiring complementary technologies. They are also expanding their global presence by establishing manufacturing hubs in key regions to meet the rising demand for cell therapies.
Additionally, these market players are working on simplifying processes to accelerate time-to-market, ensuring that therapies can be scaled rapidly in response to the growing demand.
Recent Developments (M&A/Partnerships/Product Launches)
Frequently Asked Questions